Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Primary Purpose : Treatment
Allocation : N/A
Interventional Model : Single Group Assignment
Masking : None (Open Label)
Primary outcome measures:
Progression Free Survival (PFS)
The authors' conclusion was: NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed Small-Cell-Lung-Cancer (SCLC).
Gregorc et al. 2018 Oncologist 23(10): 1133-e112…